Searched for
PHARMA BUSINESS
Mynd Fintech, part of Treds platform M1xchange, acquires C2FO IndiaM1xchange is an RBI-licensed Treds (Trade Receivables Electronic Discounting System) entity. C2FO runs C2Treds and also has the same licenc...- New rules simplify drug launches, reduce manufacturer liability for overchargingNew rules now allow drug manufacturers to launch similar medicines without prior price approval, streamlining market entry. Companies can s...
- For low risk-takers: 5 large-caps from different sectors with an upside potential of up to 31%Now, there is nothing wrong with being bullish, because it has always paid to be bullish. Yes, one might argue that it has not paid in the ...
- Stock picks of the week: 5 stocks with consistent score improvement and upside potential of up to 28%It is quite likely that the news cycle this and the next week will be about the direction of US interest rates and yield. If that turns out...
- Should they now be part of a long-term investing framework? 7 healthcare stocks with upside potential of up to 25%India’s healthcare market may grow steadily, but hospital chains can grow faster as formalisation continues. Healthcare is all about market...
- Stocks in news: Waaree Energies, Kotak Bank, HDFC Bank, Strides Pharma, Persistent SystemsIndian markets showed volatility, ending nearly flat despite positive signals. Analysts note Nifty faces resistance from key moving average...
- For investors with ability – and patience to wait 3 years, not 3 months: 6 large-cap stocks with upside potential of up to 33%The interesting point about the large-cap space today is not that prices have collapsed. In most cases, they have not. The more important c...
- Strides Pharma sells majority stake in arm Pivot Path for Rs 100 croreStrides Pharma Science has divested a majority stake in its subsidiary, Pivot Path, for Rs 100 crore to a consortium led by Ascent Capital ...
- Trade disruptions, API dependence, compliance costs: Pharma MSMEs spell out policy priorities on World MSME DayIndian pharmaceutical MSMEs are facing immense pressure from rising costs, supply chain woes, and stringent regulations. Industry represent...
- Pharma, power & mid-sized banks: Where Mayuresh Joshi is putting money to work right nowIndian markets are showing signs of recovery as geopolitical tensions ease, paving the way for a stronger earnings outlook in the second ha...
- Why Rakesh Jhunjhunwala bought Titan shares when everyone else was selling? Raamdeo Agrawal explainsRaamdeo Agrawal recalls Rakesh Jhunjhunwala’s exceptional ability to spot undervalued stocks and build long-term wealth, highlighting his f...
- Oil slide powers India's stock benchmarks to longest weekly winning run 7 monthsIndian stock markets achieved their longest winning streak in seven months, with the Nifty 50 and BSE Sensex closing higher. Falling crude ...
- India's CDMO industry set for global shift as pharma diversifies beyond China: Sai Life SciencesIndian contract manufacturers are poised for significant growth as global pharmaceutical giants diversify away from China. Companies like S...
- RICE Adamas Group expands national footprint with Mumbai Office inaugurationAdamas University and Adamas Tech Consulting have launched a new Mumbai office and the Adamas School of Experiential Learning, offering 10-...
- Nominal GDP growth could fuel largecap recovery; pharma, auto ancillaries remain preferred bets: Shreyash DevalkarIndian stock markets are defying foreign investor caution, driven by resilient June-quarter earnings. Companies are navigating geopolitical...
- India's growth story, not AI trade reversal, will drive foreign flows: Sameer DalalIndia's economic strength, not AI's decline, will drive foreign capital inflows, according to Sameer Dalal. He believes AI's market correct...
- Why Meta tapped Kunal Shah; Beauty’s new factory boomHappy Wednesday! Meta just handed WhatsApp’s steering wheel to Cred’s Kunal Shah, betting he can turn India’s favourite chat app into a pay...
- Stocks in news: Vedanta, Honasa Consumer, IRCTC, Bajaj Auto, Tata MotorsIndian markets experienced profit booking, falling over a percent amidst a weak global trend. Key stocks like Vedanta, Honasa Consumer, IRC...
- Biosimilars and innovation will drive Indian pharma's next growth phase: Vishal ManchandaIndia's pharmaceutical sector is pivoting beyond generics, with companies aggressively pursuing growth in biosimilars, nutraceuticals, and ...
- Cipla shares jump 4% as Citi puts stock on 90-day catalyst watch. What's driving the optimism?Cipla's stock surged following Citi's 'Buy' rating and a 90-day Positive Catalyst Watch. The brokerage anticipates growth from potential US...
Load More
